The Aduhelm Files Biogen touted Aduhelm, its new drug for Alzheimer's disease, as a boon to people with mild dementia. An 18-month investigation by two committees of the U.S. House of Representatives, which was released today, has a vastly different take: Aduhelm is largely the story of a drug company that chose to maximize its potential profits at the expense of patients and taxpayers. Investigators concluded the approval was "rife with irregularities," including dozens of undisclosed calls and emails between Biogen and the FDA, and an "inappropriate" level of coordination between the drugmaker and regulators. Takeaways include that Biogen knew Aduhelm could be a budget-breaker for Medicare.
In a three-part package, STAT — which has previously told the story of Aduhelm's approval and downfall in numerous investigative stories — explains the significance of the House report's revelations. Read More If you’d like to stop receiving these alerts, click on the "update email preferences" link below. | 
No comments